BCL2 and gastrointestinal stromal tumor: The research of Xu et al. pointed out that GIST cells administrated with both miRNA-22-3p mimics and cisplatin would have lower survival rate and BCL-2/BCL-2 associated X (Bax) ratio, and higher apoptosis rate and Caspase-3 level than those treated with cisplatin merely (Xu et al., 2018).